Due to the spread of antibiotic-resistant strains of Neisseria gonorrhoeae, existing treatments for gonorrhea, the sexually transmitted infection caused by the bacterium, are no longer effective. In the absence of a vaccine, there is an urgent need to develop novel treatment options.
“It’s becoming much more difficult to treat gonorrhea infections as a result of antibiotic resistance,” said Christopher Davies, Ph.D., a professor in the Department of Biochemistry and Molecular Biology at the Medical University of South Carolina. “Antibiotics that used to work against the bug are no longer effective.”
Davies and his team report surprising findings about antibiotic resistance in the May 22, 2020 issue of the
Journal of Biological Chemistry
, showing that mutations in an essential protein responsible for resistance affect the binding of the antibiotic to the microbe. Rather than directly blocking binding of the antibiotic, the mutations prevent movements in the protein that help form the binding site for the antibiotic. The findings could offer a strategy for developing new treatments that overpower antibiotic resistance. Avinash Singh, Ph.D., a postdoctoral fellow in the Davies laboratory, is lead author of the article.
N. gonorrhoeae acquires resistance to antibiotics via interactions with so-called commensal species of Neisseria that colonize mucosal surfaces, such as those in the throat and genital tract, but do not cause disease. These species develop resistance following exposure to antibiotics that someone has taken for an infection. The commensal bacteria then transfer sections of genes responsible for antibiotic resistance not only among themselves, but also to disease-causing N. gonorrhoeae during gonorrhea infections. Once N. gonorrhoeae have incorporated these genes, they develop resistance and are no longer treatable with current antibiotics.
Overpowering that resistance will require more than a genetic understanding of how resistance arises.
“We need to understand what that resistance means at the molecular level,” said Davies. “Only then can we address antimicrobial resistance by designing new antimicrobials to replace those that are no longer effective.”
In recent years, cephalosporins have been the main drugs used to treat gonorrhea. Like penicillin, they target essential bacterial proteins, called penicillin-binding proteins (PBPs), that are responsible for the construction of cell walls. Bacteria need their cell walls to maintain cell shape and integrity. When a PBP is inhibited by a cephalosporin, the bacterial wall develops holes, resulting in the death of the microbe.
Gonorrhea can become resistant to cephalosporins when the PBP drug target mutates. Davies’ group looked at the effect of those mutations on the structure of a PBP called PBP2 from a cephalosporin-resistant strain of gonorrhea.
The researchers compared the molecular structure of PBP2 in the antibiotic-resistant strain to that of an antibiotic-susceptible strain.
To their surprise, they found that the mutations prevented changes in the shape of PBP2 that are necessary for the antibiotic to bind to the protein.
Typically, mutations that confer antibiotic resistance occur in the so-called active site of proteins and block binding. But in PBP2, several of the mutations are quite a distance away. These distant mutations seem to be restricting shape changes in PBP2 that normally allow the antibiotic to interact with the protein and kill the microbe.
Once scientists understand the molecular mechanisms behind antibiotic resistance, they will be able to create new generations of antibiotics designed to avoid or overpower these mechanisms.
Knowing the important mutations that cause resistance will also allow treatments to be tailored for specific strains of N. gonorrhoeae. Patterns of resistance mutations could then be used to develop diagnostic kits to identify the strain with which a patient is infected, enabling doctors to prescribe the most appropriate antibiotics.
###
About the Medical University of South Carolina
Founded in 1824 in Charleston, MUSC is the oldest medical school in the South as well as the state’s only integrated academic health sciences center with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and 800 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. The state’s leader in obtaining biomedical research funds, in fiscal year 2019, MUSC set a new high, bringing in more than $284 million. For information on academic programs, visit
http://musc.
edu
.
As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality patient care available while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians’ practice plan and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2019, for the fifth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit
http://muschealth.
org
.
MUSC and its affiliates have collective annual budgets of $3.2 billion. The more than 17,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care.
This part of information is sourced from https://www.eurekalert.org/pub_releases/2020-05/muos-iim052220.php
